标题 |
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a phase 1/2 clinical study
SPL84(一种用于治疗3849+10kb C->T突变囊性纤维化患者的吸入反义寡核苷酸)的安全性和毒性特征支持1/2期临床研究
|
网址 | |
DOI | |
求助人 | |
下载 |